

12

EUROPEAN PATENT APPLICATION

A61L27/00 R4 A

②1 Application number: 81305048.1

⑤1 Int. Cl.³: A 61 F 1/00

22 Date of filing: 26.10.81

③ Priority: 06.11.80 US 204529

(7) Applicant: Homsy, Charles A., 11526 Raintree Cir.,
Houston Texas 77024 (US)

④ Date of publication of application: 19.05.82
Bulletin 82/20


(72) Inventor: Homsy, Charles A., 11526 Raintree Cir.,
Houston Texas 77024 (US)

⑧4 Designated Contracting States: CH DE FR GB IT LI SE

74 Representative: **Lambert, Hugh Richmond et al, D. Young & Co.** 10 Staple Inn, London WC1V 7RD (GB)

54 Structure for In vivo implantation.

57) A tension structure suitable for in vivo implantation e.g. as a substitute tendon or ligament having a plurality of longitudinal strands 16 of a biocompatible fabric 12 with the ends of the strands in the fabric and bonded with a film 14, and a sleeve of a biocompatible polymer 42 surrounding the strands, the strands being slidable with respect to each other and movable in the sleeve for adjusting their relative positions whereby the structure load is substantially uniformly distributed among the strands and a means on the ends of the structure for securing the structure in implanted position. The structure is preferably formed by removing the transverse (fill) strands 18 of a biocompatible fabric between the bonded ends of the fabric, to leave only an array of parallel warp strands between the bonded ends. In one embodiment the strands form a continuous loop the ends of which project from opposite ends of the protective sleeve 42 to form loops 48 at opposite ends for in situ attachment of the structure.



This Page Blank (uspto)

STRUCTURE FOR IN VIVO IMPLANTATION

The present invention relates to an improved structure suitable for in vivo implantation as a tension member, such as a ligament or a tendon.

Some ligament and tendon damage is not repairable by surgery except by transplant or by the implantation of prepared structures. One requirement for such structures is that they should have extended fatigue resistance so that their replacement by surgery is not required during the normal patient life.

The problems of attachment of the ends of the implanted tension structure, of causing a tunnel to form to allow sliding movement of the implanted tension member and of biocompatibility have been solved by the structure disclosed in U.S. Patent No. 4,127,902. However, increased fatigue resistance is advantageous in such implantable structures.

The present invention seeks to provide an improved implantable structure which has improved flexural characteristics and fatigue resistance and which provides a potential for longer use when implanted in vivo as a substitute ligament or tendon.

According to the present invention, a structure suitable for in vivo implantation as a tension member is provided comprising a plurality of parallel strands extending between the film bonded ends such strands having sufficient lubricity so as to slide relatively easily with respect to each

other, the film bonded fabric ends and strands being formed into an elongate structure, a tubular sheath surrounding the central portion of the elongate element and bonded near at least one end to the film. Such structure allows each of the strands to carry a substantially equal share of the load independent of the flexing of the structure.

The invention is further explained with reference to the accompanying drawings, wherein:-

Figure 1 is a plan view of structure according to the present invention at an intermediate stage of manufacture, i.e. before removal of the transverse strands of the fabric and folding over of the sealed ends to form an artificial ligament or tendon in accordance with the invention;

Figure 2 is a plan view, partially cut away, of a preferred form of a tension structure in accordance with the invention with portions broken away to show the interior structure;

Figure 3 is a sectional view of the structure taken along line 3-3 in Figure 2;

Figure 4 is a view of the initial form of the tendon structure of Figure 5, illustrating the longitudinal fibers in a loop;

Figure 5 is a view of the tendon structure of the invention;

Figure 6 is a partial view of the preferred tendon structure showing a means for attaching the tendon in its implanted position.

As shown in Figure 1, the implantable tension structure 10 of the present invention is formed from a strip 12, the opposite ends of which are bonded by films 14. Fabric 12 and films 14 are both of biocompatible material and fabric 12 is heat stable at the temperature used for the bonding

of films 14 on the ends of fabric. The material of the films 14 is preferred to be a perfluorocarbon, a perfluoroalkoxy fluorocarbon, a high molecular weight polyethylene, a hydrohalocarbon or a halocarbon.

The preferred material of the fabric 12 is 'Leno-weave' fabric of polyamide (nylon) material, such as polyaramide, sold by DuPont Company under the trade mark 'Nomex'. Such fabric is available from Stern & Stern, Inc. of Hornell, New York as fabric type HT-63-30. Other fabrics suitable for the invention are polytetrafluoroethylene fabric, polyimide fabric and polyester fabric. In such fabrics, the strands or fibers extending in one direction (longitudinal or warp strands 16) are disposed in twisted pairs and the fibers or strands extending in the perpendicular or transverse direction (fill strands 18) pass through the twisted pairs of the warp strands 16.

As used herein, the terms strand and fiber are used to mean the elements of the fabric and are not intended to exclude monofilaments.

Before or after the films 14 are bonded to the ends of the fabric 12, the fill strands 18 are removed from the intermediate portion of the fabric strip 12 which is between the films 14 so that only warp strands 16 remain between the bonded ends after bonding. This leaves a structure of a plurality of parallel strands with their ends bonded by the films 14.

Since it is desired that strands 16 be easily slidable with respect to each other, they are preferably coated with a biocompatible resin to improve their lubricity. This is accomplished by immersing strands 16 in a slurry of a suitable polytetrafluoroethylene resin such as is available from DuPont Company under the trade mark Teflon T-6 in a suitable wetting

liquid, such as isoparaffine solvent marketed by Exxon Chemical Company under the mark Isopar E. The slurry is prepared by adding 9.9 grams of the Teflon T-6 resin to 600 cc of Isopar E and blending for sufficient time (5 minutes) to develop an intimate dispersion. With the blender on, the strands are dipped into the slurry for a period of time sufficient to coat strands 16, as for example one-half minute to five minutes. Strands 16 are removed from the slurry and the solvent evaporated, for example, by drying in an oven for two hours. This procedure has been found to provide a substantially uniform coating of the strands with particles of the Teflon T-6 resin.

Thereafter, the film coated ends and strands 16 are folded into a compact rectangular shape as shown in Figure 3 and inserted into a protective sleeve 22 of a suitable biocompatible polymer, said sleeve being bonded at at least one end to one of the films 14 of bonding resin. The sleeve 22 is thus secured to the structure whilst permitting relative sliding movement and flexing of the individual strands 16 within the protective sleeve. The protective sleeve 22 is preferably a porous biocompatible polymer e.g. of Teflon (Registered Trade Mark) TFE, wherein the porosity of the sleeve is in the range from 50 to 90 percent by volume and preferably 60 percent. The material of such sleeve is preferred to be the material described in my European Application No. filed concurrently herewith, and to which reference should be made for full details. Briefly, however, such material is a porous, fibrous structure consisting of polytetrafluoroethylene fibers in a matrix of polytetrafluoroethylene resin obtained by forming a blend of the polytetrafluoroethylene fibers and the polytetrafluoroethylene and from 50-90% by volume of a particulate pore-

forming agent, e.g. sodium chloride, compacting and sintering the blend to form a fused sheet structure and leaching out the pore-forming agent.

Sleeve 22 is formed around a mandrel by heat and pressure during the sintering operation. During this process the outer surface of sleeve 22 is annealed so that some of the resin melts and covers the outer surface to reduce its pore openings and thereby provide a surface which inhibits the ingrowth of tissue. However, when maximum surface porosity is desired to enhance tissue ingrowth, as for example when the structure is to be used for replacement of the collateral ligaments of the knee, the occluding resin skin on the sleeve can be removed by mild mechanical abrasion. Conversely the surface porosity can be totally obliterated in order for the structure to be suitable as a substitute tendon. One method of achieving this is by coating the surface of the sleeve with medical grade silicone rubber for example by dipping or spray coating the sleeve with a dispersion of medical grade silicone rubber in a non-polar vehicle such as a halogenated ethylene, e.g. chlorthene solvent. It has been unexpectedly found that such thin coatings of silicone rubber are tenaciously bound to the surface of the sleeve. Since polytetrafluoroethylene is well known for its resistance to adhesion to other materials especially non-polar materials such as silicone rubber, the tenacity of attachment of the coating on the sleeve is surprising.

Furthermore, it has been found that vacuum impregnation of the entire porosity of the sleeve with said dispersion of silicone rubber followed by appropriate drying and curing of the rubber yields a novel composite of PTFE polymer and silicone rubber elastomer. This composite

retains the flexibility of the porous PTFE sleeve material but exhibits enhanced resiliency, toughness and flexural fatigue behaviour. By appropriate adjustment of the vacuum impregnation conditions the depth of impregnation of the silicone rubber into the porous PTFE sleeve material can be controlled and can produce a silicone coating more tenaciously bound than that achieved by the simple dipping or spraying procedures described above.

Sleeve 22 is positioned around the formed structure and the short length of each end, not less than 1 cm is bonded by heat to the film covered portion of the structure. Surface occlusion with silicone rubber may be carried out after this step.

Alternatively, the sleeve 22 may be wholly of silicone rubber, or other biocompatible polymer.

Thus, a complete structure is formed suitable for implantation in vivo in substitute for a ligament. The strands 16 within sleeve 22 are free to move therein to adjust their positions so that with the flexural loading of the structure along this portion of the structure, stress is substantially uniformly distributed to the strands in all positions of flexion. Also, sleeve 22 protects strands 16 from abrasion or other damage by reason of engagement by or between tissue elements, such as bones, cartilage or soft tissue. One end of substitute ligament structure is formed in a reduced size to provide a leader 24 which eases the insertion of the end through a hole in a bone.

As shown in Figure 2, a means is provided on the ligament prosthesis to protect sleeve 22 from damage in the area where the structure

enters or leaves a hole in bone. Such protection means is advisable since both ends of drilled holes or tunnels usually are not always available to the surgeon for rounding the entrances and exits to and from such tunnels. The preferred form of such protection means is skirt 26 of previously described polytetrafluoroethylene in the form of a tube four to five centimeters long with one to two centimeters at either end of skirt 26 being bonded to the exterior of sleeve 22 at either or both ends of sleeve 22 depending upon the mode of implantation. Skirt 26 may be shaped so that it does not totally encircle sleeve 22 along the free (unbonded) length as shown in Figure 2 or may be a tube of uniform length.

An additional protection means is provided in the form of protective sheath 28 which is tubular in shape and is formed of Nomex fabric and a perfluorcarbon film such as that sold by DuPont under the trade mark Teflon FEP with the FEP film overlapping but with a longitudinal gap between the Nomex fabric. Sheath 28 is secured around the portion of structure close to leader 24 and extends over a substantial portion of sleeve 22 so that it is protected in threading into its implanted position. Then leader 24 is cut from the positioned structure and the bonded portion of sheath 28 is removed with such cut and sheath 28 is easily cut longitudinally in that film portion which is free of fabric and removed from the implant structure and discarded.

In order to provide in situ bonding of the ends of the tension structure in vivo the opposite ends of the structure are preferably further coated with a layer 20 of porous biocompatible polymeric material which promotes the ingrowth of tissue within the pores of the material. Such a

material, and a suitable anchoring arrangement for the tension structures of the present invention are described in my U.S. Patents 3,992,725 and 4,129,470, to which reference should be made. Broadly speaking that material is a fibrous polymeric material having a critical surface tension in the range 25-80 dynes per centimeter and preferably comprising a blend of polytetrafluoroethylene and carbon fibers in a porous polytetrafluoroethylene resin matrix obtained by compacting and sintering a blend of polytetrafluoroethylene fibers, carbon fibers, particulate polytetrafluoroethylene resin and a particulate pore-forming agent, and subsequently leaching out the pore forming agent from the sintered matrix. Another suitable ingrowth promoting material is a velour material of polyester fiber.

Alternative means of anchoring or joining the tension structure of this invention to in situ tissue may also be employed.

A similar structure 30 suitable for in vivo implantation as a substitute tendon is shown in Figures 4, 5 and 6. Fabric 32 is similar to fabric 12. Teflon FEP film 34 is bonded to the ends of fabric 32 and then the two ends are bonded together to form the loop 40. The transverse strands of fabric 32 are removed either after film 34 is bonded to its ends or after loop 40 is formed to leave the longitudinal strands 36. Strands 36 are immersed in the Teflon T-6-Isopar-E slurry for coating as previously described. Loop 40 is inserted into tube 42 with fabric ends 32 and film 34 immediately within one end of tube 42. Such tubes are easily flexible and may be formed of non-porous material such as silicone rubber or porous material having no external porosity or only small dimension exterior porosity not efficient for tissue ingrowth. Tube 42 is approximately three millimeters in diameter and

of sufficient length for the particular tendon application. One end 44 of tube 42 is bonded to film 34 and fabric ends 32 by suitable heat and pressure or silicone adhesive. The other end 46 is sealed with a silicone rubber. Thus, entry of materials or tissue into the interior of the tube 42 is prevented.

Tube 42 may be made from the same material as the material of sleeve 22 previously described. However, for implantation of such material in a substitute tendon application, any pores in the outer surface of tube 42 are occluded by annealing in the sintering process or by coating with silicone rubber as previously described. This provides a surface which inhibits the ingrowth of tissue so that the substitute tendon is not prevented from free sliding movement in its implanted position. Tube 42 may also be a polytetrafluoroethylene vascular graft material sold by W.L. Gore and Associates of Flagstaff, Arizona under the mark Gore-Tex. This material must also have external pores occluded by coating with silicone rubber as previously described or other suitable means.

Structure 30, as shown in Figure 5, includes strands 36 extending from the ends of tube 42 in the form of loops 48. Ingrowth material 50 may be secured in one or both of loops 48 by silicone rubber as shown in Figure 6. Ingrowth material 50 is preferred to be the porous material of graphite fibers bonded with tetrafluoroethylene as disclosed in my prior U.S. Patent No. 3,992,725. A material of polyester fiber velour would also be suitable.

Thus, tendon replacement structure 30 has a plurality of strands 36 having sufficient lubricity to adjust their positions relative to

each other and are contained within tube 42 which is sufficiently large and flexible to allow such position adjustment so that each strand carries substantially all of its share of the load in all positions of the implanted structure, reduces interfiber wear and the strands are protected from damage by rubbing against bone or being caught between bones and crushed.

It is preferred that the tube or sleeve in which the strands are positioned have an internal cross-sectional area which is approximately twice the cross-sectional area occupied by the strands so that the strands are not restricted from their desired position adjustment to assume their share of the load.

It is understood that all materials used in the improved tension structures are to be biocompatible.

CLAIMS

1. A tension member for in vivo implantation characterised in that it comprises a plurality of parallel strands 16 of a biocompatible polymer readily slideable with respect to each other and bonded together at their opposite ends by a bonding film 14 of biocompatible bonding resin in which the ends of the strands are embedded, and a protective sleeve 22 of biocompatible polymeric material surrounding said strands intermediate their bonded ends and bonded at at least one end to a said film of bonding resin.

2. A tension member according to claim 1, characterised in that the said plurality of parallel strands 16 are provided by the warp strands of a length of woven fabric of biocompatible fibres, the ends of which fabric are bonded by said films 14 of bonding resin, and the fill strands of which have been removed from the length of fabric intermediate said bonded ends, thereby leave said warp strands in separate parallel array.

3. A tension member according to claim 1 or 2, characterised in that said parallel strands 16 are lubricated by coating with a surface coating of biocompatible polytetrafluoroethylene resin.

4. A tension member according to claim 1, 2 or 3, characterised in that said parallel strands 36 are formed into an endless loop 40 and joined at their opposite ends by a common film 34 of biocompatible bonding resin in which the ends of said strands are embedded, said loop being

inserted in said sleeve 42 with its opposite ends projecting therefrom to form anchoring loops for attachment of the tension member when making the implant.

5. A tension member according to claim 4, wherein one or both exposed ends of said loop is or are engaged with an anchoring member 50 of porous biocompatible polymeric material which promotes the ingrowth of tissue in the material when placed in situ.

6. A tension member according to any one of claims 1-5, characterised in that the protective sleeve 22 is of a porous biocompatible polymer.

7. A tension member according to claim 6, characterised in that the external surface of the protective sleeve 22 is treated to resist ingrowth of tissue into the sleeve.

8. A tension member according to claim 7, wherein the external surface of the sleeve 22 is annealed.

9. A tension member according to claim 7, wherein at least the surface pores of the sleeve 22 are occluded with silicone rubber.

10. A tension member according to claim 8, wherein the porous sleeve is substantially completely impregnated with silicone rubber.

11. A tension member according to claim 6, wherein the protective sleeve 22 has an open porous surface which promotes the ingrowth of tissue into the sleeve.

12. A tension member according to any one of claims 6-11, wherein the protective sleeve 22 is formed of a biocompatible polymeric material comprising fibers of polytetrafluoroethylene in a porous matrix of polytetrafluoroethylene bonding resin.

13. A tension member according to any one of claims 1-5, wherein said sleeve is of silicone rubber.

14. A tension member according to any one of the preceding claims, wherein the parallel strands 16, 36 are of polyamide, polyimide, polytetrafluoroethylene or polyester and said bonding film 14, 34 is a perfluorocarbon polymer, a perfluoroalkoxy fluorocarbon polymer or high molecular weight polyethylene.

15. A tension member according to any one of claims 1-3 or 6-14 as dependent thereon, wherein the ends of the structure adjacent the bonding films 14 are coated with a layer 20 of porous biocompatible polymeric material which promotes the ingrowth of tissue within the pores of the polymeric material.

16. A tension member according to claim 5 or 15, wherein the porous biocompatible polymeric material comprises a blend of polytetrafluoroethylene and carbon fibers in a porous matrix of polytetrafluoroethylene resin.

17. A tension member according to claim 5 or 15, wherein the porous polymeric material is a polyester fiber velour.

18. A tension member according to any one of the preceding claims, characterised in that at least one end of the sleeve 22 is protected by a protective skirt 26 of biocompatible material mounted around said sleeve and extending along at least part of the length thereof.

19. A tension member according to claim 18, characterised in that said skirt 26 comprises a tubular member coaxial with the end of said sleeve 22 and bonded thereto.

20. A tension member according to any one of the preceding claims, characterised in that at least one end of the structure is externally protected by a removable sheath 28 to protect said sleeve from damage prior to or during implantation and removable from said structure after implantation.

21. A tension member according to claim 20, characterised in that the externally protected end of the structure is of a reduced dimension to provide a leader 24 for insertion of the structure during implantation, said sheath 28 being bonded to said leader and removable therewith after implantation of the structure.




FIG.1







FIG.2






FIG. 4




FIG. 6




FIG. 5

-3- BASIC DOC.-

A61L17/00P4



Office européen des brevets

⑪ Publication number:

0051954

A3

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 81305048.1

⑮ Int. Cl. 3: A 61 F 1/00

⑭ Date of filing: 26.10.81

⑯ Priority: 06.11.80 US 204529

⑰ Applicant: Homsy, Charles A., 11526 Raintree Cir.,
Houston Texas 77024 (US)

⑲ Date of publication of application: 19.05.82
Bulletin 82/20

⑳ Inventor: Homsy, Charles A., 11526 Raintree Cir.,
Houston Texas 77024 (US).


㉑ Designated Contracting States: CH DE FR GB IT LI SE

㉒ Date of deferred publication of search
report: 11.08.82 Bulletin 82/32

㉓ Representative: Lambert, Hugh Richmond et al, D.
YOUNG & CO. 10 Staple Inn, London, WC1V 7RD (GB)

㉔ Structure for in vivo implantation.

㉕ A tension structure suitable for in vivo implantation e.g. as a substitute tendon or ligament having a plurality of longitudinal strands 16 of a biocompatible fabric 12 with the ends of the strands in the fabric and bonded with a film 14, and a sleeve of a biocompatible polymer 42 surrounding the strands, the strands being slidable with respect to each other and movable in the sleeve for adjusting their relative positions whereby the structure load is substantially uniformly distributed among the strands and a means on the ends of the structure for securing the structure in implanted position. The structure is preferably formed by removing the transverse (fill) strands 18 of a biocompatible fabric between the bonded ends of the fabric, to leave only an array of parallel warp strands between the bonded ends. In one embodiment the strands form a continuous loop the ends of which project from opposite ends of the protective sleeve 42 to form loops 48 at opposite ends for in situ attachment of the structure.



A3

A4

A5

A6

A7

A8

A9



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 2)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D, Y	US-A-4 127 902 C.A. HOMSY * Figure 6; column 4, lines 29-46; figure 3; column 3, lines 67-68; column 4, lines 1-6 *	1-21	A 61 F 1/00
Y	US-A-3 973 277 J.C. SEMPLE et al. * Column 2, lines 34-60; figure 1 *	1-21	
A	FR-A-2 135 825 RHONE-POULENC * Claim 2; figure 1 *		
A	FR-A-2 395 012 GENERAL ATOMIC * Figure 2 *		
D, A	US-A-4 129 470 C.A. HOMSY * Column 10, lines 29-42 *	16	A 61 F
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
Place of search	Date of completion of the search	Examiner	
THE HAGUE	15-04-1982	PELTRE C.H.	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone		T : theory or principle underlying the invention	
Y : particularly relevant if combined with another document of the same category		E : earlier patent document, but published on, or after the filing date	
A : technological background		D : document cited in the application	
O : non-written disclosure		L : document cited for other reasons	
P : intermediate document		& : member of the same patent family, corresponding document	